Avalo Therapeutics (AVTX) EBIT (2014 - 2026)

Avalo Therapeutics (AVTX) has 13 years of EBIT data on file, last reported at -$20.9 million in Q1 2026.

• Quarterly EBIT fell 42.48% year-over-year to -$20.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$79.2 million (down 57.01% YoY) and the FY2025 annual result came in at -$72.9 million, down 6.44% from the prior year.
• EBIT eased to -$20.9 million in Q1 2026, from -$19.7 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $4.1 million in Q3 2022 to a low of -$32.8 million in Q1 2024.
• A 5-year average of -$13.4 million and a median of -$12.9 million in 2024 frame the typical range for EBIT.
• Annual changes were most pronounced in 2022 — EBIT soared 124.87% — and 2024, when it slumped 272.69%.
• Tracing AVTX's EBIT over 5 years: stood at -$8.9 million in 2022, then advanced by 13.52% to -$7.7 million in 2023, then tumbled by 73.82% to -$13.3 million in 2024, then tumbled by 48.31% to -$19.7 million in 2025, then decreased by 5.87% to -$20.9 million in 2026.
• The last three EBIT figures came in at -$20.9 million (Q1 2026), -$19.7 million (Q4 2025), and -$19.2 million (Q3 2025), per Business Quant data.